Sarepta names former Allergan executive as new CEO

Sarepta Therapeutics, the Cambridge biotech that won approval last year for the first-ever Duchenne muscular dystrophy drug, said Wednesday that it had appointed former Allergan executive Douglas Ingram as its new CEO. Sarepta (Nasdaq: SRPT) had been searching for a new CEO after Ed Kaye announced in April that he planned to step down. Ingram served as president of Allergan until the company was acquired by Actavis in 2015. More recently, he was CEO of Chase Pharmaceuticals, a California biotech…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news